Therapeutic vaccination for closed head injuryKIPNIS, Jonathan; NEVO, Uri; PANIKASHVILI, David et al.Journal of neurotrauma. 2003, Vol 20, Num 6, pp 559-569, issn 0897-7151, 11 p.Article

Specific vaccines against autoimmune diseasesSELA, M.Comptes rendus de l'Académie des sciences. Série 3, Sciences de la vie. 1999, Vol 322, Num 11, pp 933-938, issn 0764-4469Conference Paper

EFFECT OF A SYNTHETIC POLYPEPTIDE (COP 1) ON PATIENTS WITH MULTIPLE SCLEROSIS AND WITH ACUTE DISSEMINATED ENCEPHALOMYELITIS.ABRAMSKY O; TEITELBAUM D; ARNON R et al.1977; J. NEUROL. SCI.; NETHERL.; DA. 1977; VOL. 31; NO 3; PP. 433-438; BIBL. 20 REF.Article

A pilot trial of COP 1 in exacerbating-remitting multiple sclerosisBORNSTEIN, M. B; MILLER, A; WEISS, W et al.The New England journal of medicine. 1987, Vol 317, Num 7, pp 408-414, issn 0028-4793Article

Methylation-dependent transcription controls plasmid replication of the CloDF13 cop-1(Ts) mutantVAN PUTTEN, A. J; DE LANG, R; VELTKAMP, E et al.Journal of bacteriology. 1986, Vol 168, Num 2, pp 728-733, issn 0021-9193Article

Application and Performance Analysis of Various AEAD Techniques for Space Telecommand AuthenticationLEI ZHANG; SPINSANTE, Susanna; CHAOJING TANG et al.IEEE transactions on wireless communications. 2009, Vol 8, Num 1, pp 308-319, issn 1536-1276, 12 p.Article

A placebo-controlled, double-blind, randomized, two-center, pilot trial of cop 1 in chronic progressive multiple sclerosisBORNSTEIN, M. B; MILLER, A; BROWN, S et al.Neurology. 1991, Vol 41, Num 4, pp 533-539, issn 0028-3878Article